Drugs / POL6014
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03748199 | Nov 2018 → Dec 2020 | cystic fibrosis | Santhera Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-03-01 | Santhera Pharmaceuticals | Results Santhera Announces Positive Results with Lonodelestat in Early Phase Cystic Fibrosis Trial santhera.com ↗
Santhera Pharmaceuticals (SIX: SANN) announces positive results from its multiple ascending dose Phase 1b study with lonodelestat, a potent inhibitor of human neutrophil elastase (hNE), in patients with cystic fibrosis (CF). |
| 2019-09-10 | Santhera Pharmaceuticals | Results Santhera Announces Publication of Phase I Clinical Data with POL6014 in Journal of Cystic Fibrosis santhera.com ↗
These data demonstrated that single dose inhalation of POL6014 can lead to high drug concentrations within the lung, resulting in inhibition of hNE in sputum of patients, an enzyme associated with lung tissue inflammation. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-03-01 | Santhera Pharmaceuticals | Santhera Announces Positive Results with Lonodelestat in Early Phase Cystic Fibrosis Trial santhera.com ↗ |
| 2020-04-27 | Santhera Pharmaceuticals | Santhera and Cold Spring Harbor Laboratory to Investigate Lonodelestat (POL6014) in COVID-19-related Acute Respiratory Distress Syndrome (ARDS) santhera.com ↗ |
| 2019-09-10 | Santhera Pharmaceuticals | Santhera Announces Publication of Phase I Clinical Data with POL6014 in Journal of Cystic Fibrosis santhera.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | POL6014 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03748199 ↗ |
| Action | Inhibit | “neutrophil elastase inhibitor” NCT03748199 ↗ |
| Route | Inhaled | “orally inhaled multiple doses” NCT03748199 ↗ |